Pulse News Wire translates Japanese corporate disclosures filed with the Tokyo Stock Exchange's TDNet system into clear, structured English for institutional investors, hedge funds, and asset managers. Every article on this page is derived directly from an official TDNet filing — including earnings reports, M&A announcements, share buybacks, dividend declarations, and governance changes. Japanese corporate governance is governed by the Companies Act and the Financial Instruments and Exchange Act; timely translation of these disclosures provides a material information advantage for cross-border investors monitoring Tokyo-listed equities.
This corporate disclosure from was processed by Pulse News Wire on February 3, 2026. It represents a primary source document for Japanese Corporate sector intelligence, translated directly from an official filing submitted to the Tokyo Stock Exchange TDNet system.
Source disclosure: February 03, 2026 AFC-HD AMS Life Science Co., Ltd. [2927.T] TOKYO, Feb 03 (Pulse News Wire) – Afc-hd AMS Life Science CO.,LTD. (2927.T) completed the exercise of its sixth tranche warrant issued to EVO Fund on February 03, 2026. A total of 5,000 warrants were initially issued, with 5,000 warrants exercised, leaving no remaining warrants outstanding. The issuance raised ¥435.5 million in funds. As of February 03, 2026, the company's issued share capital stands at